Author

Robert G. Hindes

Observed names: HINDES RG, R G Hindes, R Hindes, R. Hindes, R.G. Hindes, Robert G Hindes, Robert Hindes

Institution: Achillion Pharmaceuticals (United States)

Observed institutions: Cedars-Sinai Medical Center, University Health Network, Ankara University, Chinese University of Hong Kong, Danbury Hospital, Taipei Veterans General Hospital, Bristol-Myers Squibb (United States), Achillion Pharmaceuticals (United States), Gilead Sciences (United States), Henry Dunant Hospital, Hacettepe University, University of Santo Tomas, Milliman (United States)

OpenAlex ID: A5111663669

Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

2014 · Mark S. Sulkowski, David F. Gardiner, et al. · New England Journal of Medicine · 1,187

Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B†,‡

2010 · Ting-Tsung Chang, Yun-Fan Liaw, et al. · Hepatology · 970

PDF

Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C

2013 · Edward J. Gane, Catherine A. Stedman, et al. · New England Journal of Medicine · 756

PDF

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

2006 · Morris Sherman, Cihan Yurdaydin, et al. · Gastroenterology · 412

PDF

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

2013 · Eric Lawitz, Jay P Lalezari, et al. · The Lancet Infectious Diseases · 331

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

2013 · Kris V Kowdley, Eric Lawitz, et al. · The Lancet · 295

A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients

2005 · Ting–Tsung Chang, Robert G. Gish, et al. · Gastroenterology · 246

PDF

Entecavir therapy for lamivudine‐refractory chronic hepatitis B

2008 · Morris Sherman, Cihan Yurdaydin, et al. · Hepatology · 166

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

2012 · Stanislas Pol, Reem H Ghalib, et al. · The Lancet Infectious Diseases · 144

Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C

2013 · R.J. Fontana, E.A. Hughes, et al. · American Journal of Transplantation · 143

PDF

1422 Potent Viral Suppression With All-oral Combination of Daclatasvir (ns5a Inhibitor) and Gs-7977 (ns5b Inhibitor), +/− Ribavirin, in Treatment-naive Patients With Chronic Hcv Gt1, 2, or 3

2012 · M. Sulkowski, D. Gardiner, et al. · Journal of Hepatology · 80

Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation

2012 · Robert J. Fontana, Eric A. Hughes, et al. · Liver Transplantation · 66

1417 Sustained Virologic Response With Daclatasvir Plus Sofosbuvir ± Ribavirin (rbv) in Chronic Hcv Genotype (gt) 1-infected Patients Who Previously Failed Telaprevir (tvr) or Boceprevir (boc)

2013 · M.S. Sulkowski, D.F. Gardiner, et al. · Journal of Hepatology · 53

PDF

Treatment of experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin

1989 · R G Hindes, S H Willey, et al. · Antimicrobial Agents and Chemotherapy · 48

Randomized Study of Asunaprevir plus Pegylated Interferon-α and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C

2013 · Jean-Pierre Bronowicki, Stanislas Pol, et al. · Antiviral Therapy · 46

PDF

Outpatient Intravenous Antibiotic Therapy in Medicare Patients: Cost-savings Analysis

1995 · Robert Hindes, Catherine Winkler, et al. · Infectious Diseases in Clinical Practice · 42

1113 Electron: Once Daily Psi-7977 Plus Rbv in Hcv Gt1/2/3

2012 · E.J. Gane, C.A. Stedman, et al. · Journal of Hepatology · 36

80 Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)

2006 · C. Yurdaydin, J. Sollano, et al. · Journal of Hepatology · 29

Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine.

2002 · Ting‐Tsung Chang, S. Hadziyannis, et al. · Hepatology · 28

1373 FIRST REPORT OF SVR12 FOR A NS5A REPLICATION COMPLEX INHIBITOR BMS-790052 IN COMBINATION WITH PEG-IFNa-2A AND RBV: PHASE 2A TRIAL IN TREATMENT-NAIVE HCV-GENOTYPE-1 SUBJECTS

2011 · S. Pol, R.H. Ghalib, et al. · Journal of Hepatology · 25

PDF

1 Atomic: 97% Rvr for Psi-7977 + Peg/rbv × 12 Week Regimen in Hcv Gt1: an End to Response-guided Therapy?

2012 · K.V. Kowdlev, E. Läwitz, et al. · Journal of Hepatology · 24

ENTECAVIR MAINTAINED VIROLOGIC SUPPRESSION THROUGH 3 YEARS OF TREATMENT IN ANTIVIRALNAı‥VE HBEAG PATIENTS (ETV 022/901)

2006 · Ting‐Tsung Chang, You‐Chen Chao, et al. · 21

1195 Bms-650032, an Ns3 Inhibitor, in Combination With Peginterferon Alpha-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Infection

2011 · J.-P. Bronowicki, S. Pol, et al. · Journal of Hepatology · 20

Effects of clindamycin and gentamicin and other antimicrobial combinations against enterococci in an experimental model of intra-abdominal abscess.

1989 · S H Willey, R G Hindes, et al. · PubMed · 18

Agranulocytosis induced by abacavir

1999 · Vadim Tikhomirov, Karim Namek, et al. · AIDS · 16

Works count: 44

Citation count: 5,265

H-index: 21

I10-index: 26